Showing papers by "Fabrice Barlesi published in 2008"
TL;DR: Unexpectedly, at the end of their hospital stay, patients receiving both oral and written information experienced a statistically significant lower level of satisfaction, whereas no difference in QoL between both groups were highlighted.
22 citations
TL;DR: A systematic review of the literature from 1996 to September 2007 on studies that assessed the role of ERCC1 in resected NSCLC found that patients treated by surgery and who receive chemotherapy, either as adjuvant therapy or for disease relapse, have a better overall survival when ER CC1 levels are low.
Abstract: Platinum-based regimens are the cornerstones of therapy in adjuvant and neoadjuvant management of early stage non-small cell lung cancer (NSCLC). However, the survival benefit associated with platinum-based chemotherapy is marginal and therefore adequate patient selection is essential. Excision repair cross complementation 1 (ERCC1) is a key-enzyme in the repair of platinum-DNA adducts that has been demonstrated to influence the response to platinum-based therapy. We performed a systematic review of the literature from 1996 to September 2007 on studies that assessed the role of ERCC1 in resected NSCLC. Overall, nine studies were identified. ERCC1 expression has been assessed by mRNA expression (n=5) and/or by protein expression (immunohistochemistry) (n=5). One study assessed ERCC1 status by both methods. In these studies, patients with early stage NSCLC treated by surgery alone survived longer if ERCC1 levels are high (favourable prognostic value of high ERCC1 level). Conversely, patients treated by surgery and who receive chemotherapy, either as adjuvant therapy or for disease relapse, have a better overall survival when ERCC1 levels are low (favourable predictive value of low ERCC1 level). ERCC1 expression might assist in selecting patients who will respond to adjuvant (neoadjuvant) platinum-based chemotherapy. However, further investigation is necessary in order to prospectively confirm these results and to ascertain the most appropriate method of assessment. Thoracic surgeons should participate in this field of research.
17 citations
TL;DR: An open-label single-arm trial evaluating the safety of first-line bevacizumab (Bev) combined with standard chemotherapy regimens, in some 2000 patients with advanced breast cancer, finds no statistically significant difference between the two treatment regimens.
Abstract: 8085 Background: MO19390 (SAiL) is an open-label single-arm trial evaluating the safety of first-line bevacizumab (Bev) combined with standard chemotherapy regimens, in some 2000 patients (pts) wit...
13 citations
TL;DR: The aim of this study was to evaluate 3 monotherapy modalities, with a focus on PS 2 or 3 patients, which are usually excluded from clinical trials.
Abstract: 8086 Background: PS 2 or 3 patients are usually excluded from clinical trials. Optimal treatment in this setting remains a challenge. The aim of this study was to evaluate 3 monotherapy modalities....
4 citations
TL;DR: This parallel phase II study was initiated to determine the efficacy of erlotinib in chemonaive pts with advanced NSCLC, at a fixed dose in NS, and a toxicity- driven dose in C/FS, and found that NS were more likely to be women than men.
Abstract: 8111 Background: Skin rash has been associated with increased activity of erlotinib in retrospective analyses and plasma levels of erlotinib are lower in current vs former or non-smokers (NS), pote...
4 citations
TL;DR: This study has been designed to compare the classical mono chemotherapy docetaxel with a docetrixel cisplatin doublet, a type of second-line chemotherapy after initial adjuvant or neoadjuvant treatment with a platinum-based regimen.
Abstract: BACKGROUND: As chemotherapy gains wider acceptance for the treatment of earlier stages of NSCLC, particularly in the adjuvant and neoadjuvant setting, physicians face a growing population of high performance status patients who have relapsed after their first-line chemotherapy. The type of second-line chemotherapy after initial adjuvant or neoadjuvant treatment with a platinum-based regimen remains largely undefined. The current study has been designed to compare the classical mono chemotherapy docetaxel with a docetaxel cisplatin doublet. METHODS: Patients will be randomized in 2 arms. Arm: docetaxel cisplatin (cycles repeated every 21 days), 4 cycles followed by 2 cycles of docetaxel alone in case of objective response or stabilisation. Arm B: docetaxel alone (cycles repeated every 21 days), 4 cycles followed by 2 cycles of docetaxel alone in case of objective response or stabilisation. EXPECTED RESULTS: 300 patients will be randomized with a statistical hypothesis of a progression free survival of 3 months in the control arm and of 4.5 months in the experimental arm.
4 citations
3 citations
TL;DR: In this article, the authors propose an approach to determine the meilleure option therapeutique chez les patients en rechute apres une association of chirurgie and chimiotherapie.
Abstract: Etat des connaissances Malgre une approche multimodale incluant la chirurgie et la chimiotherapie, 2/3 des patients presentent une evolution de leur maladie. Cette situation de rechute chez des patients traites par chimiotherapie peri operatoire (adjuvante, neoadjuvante ou les 2) est nouvelle. Cette etude de phase III se propose de determiner la meilleure option therapeutique chez les patients en rechute apres une association de chirurgie et chimiotherapie. Methodes Les patients seront repartis de facon aleatoire entre deux groupes de traitement. Dans le groupe A, les patients recoivent du cisplatine et du docetaxel. Le traitement est repete toutes les 3 semaines, jusqu’a quatre cures. Dans le groupe B, les patients recoivent le docetaxel seul. A l’issue des quatre cures, les patients dont la maladie est stable ou en reponse sont traites par deux cures supplementaires de docetaxel. Resultats attendus Trois cents patients seront inclus avec des hypotheses statistiques basees sur une mediane de survie sans progression de 3 mois dans le groupe controle et de 4,5 mois dans le groupe experimental.
1 citations
TL;DR: Cette etude de phase III se propose de determiner la meilleure option therapeutique chez les patients en rechute apres une association de chirurgie & chimiotherapie chez des patients traites par chimi otherapie peri operatoire.
Abstract: Etat des connaissances Malgre une approche multimodale incluant la chirurgie et la chimiotherapie, 2/3 des patients presentent une evolution de leur maladie. Cette situation de rechute chez des patients traites par chimiotherapie peri operatoire (adjuvante, neoadjuvante ou les 2) est nouvelle. Cette etude de phase III se propose de determiner la meilleure option therapeutique chez les patients en rechute apres une association de chirurgie et chimiotherapie. Methodes Les patients seront repartis de facon aleatoire entre deux groupes de traitement. Dans le groupe A, les patients recoivent du cisplatine et du docetaxel. Le traitement est repete toutes les 3 semaines, jusqu’a quatre cures. Dans le groupe B, les patients recoivent le docetaxel seul. A l’issue des quatre cures, les patients dont la maladie est stable ou en reponse sont traites par deux cures supplementaires de docetaxel. Resultats attendus Trois cents patients seront inclus avec des hypotheses statistiques basees sur une mediane de survie sans progression de 3 mois dans le groupe controle et de 4,5 mois dans le groupe experimental.